"ABBOTINDIA: हेल्थकेयर का भरोसेमंद साथी, भविष्य की दवा में अग्रणी!"

Technical Analysis

Current price ₹26,460 (-1.69%, Feb 13, 2026 close), open ₹26,680, high ₹26,685, low ₹26,300; 52W high ₹37,000/low ₹26,300. Strong Sell signals: Most MAs bearish (MA5 ₹34,372 Sell to MA200 ₹33,680 Buy - 9 Sell/3 Buy), RSI 41 Sell, STOCH 97 Overbought, MACD +54 Buy but ADX 43 Sell, CCI -82 Sell; high volume ₹275. Pivot levels: PP ₹31,387-34,187, R1 ₹31,810-34,274, S1 ₹30,525-34,103; key support ₹30,020-29,240, resistance ₹32,590-34,443. Downtrend persists but STOCHRSI oversold hints at reversal if ₹26,300 holds. Continuous Downfall Reasons/Reversal Outlook Yes, 25% decline from ₹37K highs: Market underperformance, weak trading momentum, investor participation down 12.51%, flat Q3 results, high valuations (P/B/PEG), profit booking. Rally unlikely to continue—reversal possible at 52W low test/oversold conditions, though downtrend dominates short-term. Long-term: Accumulate given zero debt/high ROE. Positive Points Q3/9M PAT +4%/7.67%, zero debt, ROE 32.53%. Budget biopharma push, new products/market share gains. High management efficiency, 1Y +21% long-term performance. Negative Points Margin pressure, QoQ revenue dip, elevated valuations. Investor participation -12.51%, short-term downtrend. STOCH overbought amid overall Strong Sell signals.